
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Rapid readout of real-world advanced melanoma care reveals treatment patterns, outcomes, and safety insights that complement trial evidence.
This abstract summarizes findings from a multicenter, retrospective real-world analysis evaluating clinical outcomes and safety in patients with advanced melanoma treated inmroutine practice. The discussion focuses on treatment patterns, observed clinical activity, and tolerability across participating centers. These insights help contextualize real-world experience alongside evidence generated from clinical studies.






